186 related articles for article (PubMed ID: 21993768)
1. Solifenacin objectively decreases urinary sensation in women with overactive bladder syndrome.
Lowenstein L; Kenton K; Mueller ER; Brubaker L; Sabo E; Durazo-Arivzu RA; Fitzgerald MP
Int Urol Nephrol; 2012 Apr; 44(2):425-9. PubMed ID: 21993768
[TBL] [Abstract][Full Text] [Related]
2. Overactive bladder syndrome: what is the role of evidence of detrusor overactivity in the cystometric study?
Vecchioli-Scaldazza C; Grinta R
Minerva Urol Nefrol; 2010 Dec; 62(4):355-61. PubMed ID: 20944536
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women.
Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
Urol Int; 2014; 93(4):470-3. PubMed ID: 25170796
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome.
Hsiao SM; Lin HH; Kuo HC
Neurourol Urodyn; 2014 Mar; 33(3):331-4. PubMed ID: 23494586
[TBL] [Abstract][Full Text] [Related]
5. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
[TBL] [Abstract][Full Text] [Related]
6. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity.
Ronchi P; Gravina GL; Galatioto GP; Costa AM; Martella O; Vicentini C
Neurourol Urodyn; 2009; 28(1):52-7. PubMed ID: 18671288
[TBL] [Abstract][Full Text] [Related]
7. Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder.
Tanaka Y; Masumori N; Tsukamoto T
Int J Urol; 2010 Sep; 17(9):796-800. PubMed ID: 20649825
[TBL] [Abstract][Full Text] [Related]
8. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms.
Brubaker L; FitzGerald MP
Int Urogynecol J Pelvic Floor Dysfunct; 2007 Jul; 18(7):737-41. PubMed ID: 17131169
[TBL] [Abstract][Full Text] [Related]
9. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
10. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes.
Ohtake A; Sato S; Sasamata M; Miyata K
J Pharmacol Sci; 2010; 112(2):135-41. PubMed ID: 20134114
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study.
Chung JH; Lee JY; Kang DH; Ha US; Lee SH; Ham WS; Cho KS; Han JH; Park J; Yoo TK; Lee SW
Neurourol Urodyn; 2012 Sep; 31(7):1175-80. PubMed ID: 22674356
[TBL] [Abstract][Full Text] [Related]
12. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
Swift SE; Siami P; Forero-Schwanhaeuser S
Clin Drug Investig; 2009; 29(5):305-16. PubMed ID: 19366272
[TBL] [Abstract][Full Text] [Related]
13. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
Liu HT; Lin H; Kuo HC
Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility of urodynamic filling sensation at weekly interval in healthy volunteers and in women with detrusor overactivity.
Van Meel TD; Wyndaele JJ
Neurourol Urodyn; 2011 Nov; 30(8):1586-90. PubMed ID: 21538500
[TBL] [Abstract][Full Text] [Related]
15. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G;
BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801
[TBL] [Abstract][Full Text] [Related]
16. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg.
Brunton S; Kuritzky L
Curr Med Res Opin; 2005 Jan; 21(1):71-80. PubMed ID: 15881477
[TBL] [Abstract][Full Text] [Related]
17. A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency.
Han JY; Lee KS; Park WH; Park CH; Lee JG; Lee JZ; Kim DY; Na YG; Kwon DD; Choo MS
PLoS One; 2014; 9(11):e112063. PubMed ID: 25401784
[TBL] [Abstract][Full Text] [Related]
18. Acupuncture versus solifenacin for treatment of overactive bladder and its correlation with urine nerve growth factor levels: a randomized, placebo-controlled clinical trial.
Aydoğmuş Y; Sunay M; Arslan H; Aydın A; Adiloğlu AK; Şahin H
Urol Int; 2014; 93(4):437-43. PubMed ID: 25033919
[TBL] [Abstract][Full Text] [Related]
19. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
